In order to survive and thrive, emerging-growth biotech and specialty pharmaceutical companies depend on the ability to strategically develop, exploit and monetize their intellectual property and product portfolios. Goodwin’s licensing and partnering practice does just that. We offer unmatched counsel and a deep bench of talented lawyers located in biotech, medical and scientific innovation centers throughout the United States. Recognized nationally and internationally as experts in the life sciences field, our lawyers advise company clients during their full life cycle, offering unmatched insight into deal terms, trends and industry drivers. Using our extensive expertise, we advise clients on a variety of complex transactions and novel deal structures, including:
- Global strategic alliances, joint ventures and collaborations
- Product acquisitions, structured acquisitions, spin-outs and divestitures
- Intellectual property licensing and royalty monetizations
- Co-development, co-commercialization, co-promotion and marketing agreements
- Research, manufacturing, supply, distribution and other services agreements
- University licenses and other foundational in-license agreements
- Settlement and license agreements for brand and generic pharmaceutical companies related to ANDA or biosimilars litigation and other patent disputes
BioPharm Insight consistently ranks us among the top five most active legal advisors for global and U.S. biotech/pharma licensing agreements. FierceBiotech named two of Goodwin’s collaboration deals in its list of all time “Top 10 Largest Upfront Deals,” and The New England Venture Capital association named one of our structured M&A deals as “2017 Exit of the Year.”
